GPT and metabolic dysfunction-associated steatotic liver disease: In a randomized controlled clinical trial, Gawrieh et al103 found that saroglitazar (4 mg) significantly improved alanine aminotransferase levels and atherosclerotic dyslipidemia in patients with NAFLD/NASH.